Survodutide and Liver Fat: The MASH Angle

Survodutide is one of several dual GLP-1/glucagon agonists, but it has drawn particular attention for its development in MASH (formerly NASH) — metabolic dysfunction-associated steatohepatitis. The glucagon component is hypothesized to act directly on hepatic lipid metabolism, on top of GLP-1's weight-loss-driven liver-fat reduction.

This thread reviews the mechanistic rationale for glucagon in liver-fat handling and how members interpret the early MASH resolution data with appropriate caution.